Aclaris Therapeutics shares are trading higher after the company announced the sale of OLUMIANT royalties and milestones to OMERS Life Sciences for up to $31.5 million.
Portfolio Pulse from Benzinga Newsdesk
Aclaris Therapeutics shares are trading higher following the announcement of the sale of OLUMIANT royalties and milestones to OMERS Life Sciences for up to $31.5 million.
July 16, 2024 | 8:04 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Aclaris Therapeutics shares are trading higher after the company announced the sale of OLUMIANT royalties and milestones to OMERS Life Sciences for up to $31.5 million.
The sale of OLUMIANT royalties and milestones provides Aclaris Therapeutics with a significant cash infusion, which is likely to be viewed positively by investors, leading to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100